Marcello Milano is a director in the R&D and Regulatory Policy team at BioMarin, a global biotechnology company that develops innovative therapies for rare genetic diseases. In his role, Marcello focuses on EU regulatory intelligence, regulatory policy development and advocacy as a member of working groups across industry organizations, including EuropaBio, EUCOPE, ARM, MPP and BIA. Amongst other roles, he acts as EUCOPE alternate in the Accelerating Clinical Trials in Europe (ACT-EU) Multistakeholder Platform Advisory Group.

Marcello has been part of the biopharmaceutical industry for about 30 years, of which nearly 20 in the regulatory affairs field, with previous roles in Chiesi and GSK. He holds a chemistry degree from the University of Padua, Italy.